Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nunzia Pharmaceutical Corp (PK:NUNZ)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for NUNZ*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Aug 16, 2021 06:30 ET
Nunzia Pharmaceutical Corporation (OTC: NUNZ), an Emerging Leader in Innovative Pharmaceutical and Nutraceuticals, is Now Offering a Patented Blood Warmer Through Nunzia's Medical Supply Division. 8K
via NewMediaWire – Nunzia Pharmaceutical Corporation (OTC: NUNZ), an Emerging Leader in Innovative Pharmaceutical and Nutraceuticals, is now offering a Patented Blood Warmer through Nunzia’s Medical Supply division. 8K filed 08/05/2021 Nunzia...
Read full article
Aug 06, 2021 07:00 ET
Nunzia Pharmaceutical Corporation (OTC:NUNZ), an Emerging Leader in Innovative Pharmaceutical and Nutraceuticals, has Signed a Licensing Agreement with Michael Mitsunaga for the Exclusive Patent Right
via NewMediaWire – Nunzi Pharmaceutical Corporation (OTC:NUNZ) entered into a License Agreement with Michael Mitsunaga as stated in the 8K filing of 08/05/2021. Under the terms of the Agreement, Nunzia has the exclusive license to use the...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-2.56
--
--
Price to Sales - TTM
--
2.45
3.32
Price to Book - most recent quarter
--
1.91
2.21
Price to Cash Flow per share - TTM
--
12.81
14.62
Price to Free Cash Flow per share - TTM
--
19.04
24.75
See all valuations

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Nunzia Pharmaceutical Corporation is a pharmaceutical company. The Company focuses on development and delivery of pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum of Disorders (ASDs) and related conditions, such as Fragile X syndrome, as well as common anxiety-based disorders. The Company has developed NUNZIA, which is a combination of 16 vitamins, minerals and herbs which directly focuses and targets the hippocampus area of the brain, where all anxiety-based disorders originate.

See business summary

 

Twitter

Search (past week) for $NUNZ

  • No tweets found